FDA Posted Ultragenyx's Rare-Disease Voucher for the First MPS IIIA Gene Therapy

So basically: On Oct. 6 the Federal Register published FDA’s notice that Ultragenyx gets a rare pediatric disease priority review voucher for FAYUVI, the first approved gene therapy for children with Sanfilippo syndrome type A. The drug itself cleared FDA on Sept. 17. Nature Reviews Drug Discovery flagged the approval on Oct. 5.

What FAYUVI is

FAYUVI is rebisufligene etisparvovec-hopf. It is an adeno-associated virus serotype 9 (AAV9) vector gene therapy given as a one-time intravenous infusion in a clinic set up to handle infusion reactions.

MPS IIIA, also called Sanfilippo syndrome type A, is a rare inherited lysosomal storage disease. Children lack working sulfamidase from the SGSH gene. Heparan sulfate builds up and damages the brain and nervous system. Kids often develop normally early, then lose cognitive, language, and other skills. Until FAYUVI, FDA said care was limited to managing symptoms.

The approved use covers neurologic manifestations in pediatric patients who still have preserved neurodevelopmental function. In the main open-label study, FDA says treated patients ages 2 to 5 held or improved cognitive scores compared with an untreated historical control group, against a natural history of plateau then decline in that window.

Common adverse reactions in more than 5% of patients included higher AST liver enzymes, nausea, vomiting, fever, lower appetite, lower white-cell and platelet counts, and higher amylase. Important warnings include thrombotic microangiopathy. As with other AAV products, there is a theoretical long-term risk that inserted genetic material could integrate and contribute to tumor risk. Patients receive corticosteroids starting one day before infusion for at least eight weeks afterward.

What the voucher is

Nature’s Oct. 5 note underscored the same point FDA made in September: FAYUVI is the first FDA-approved therapy aimed at changing the course of MPS IIIA, not only easing symptoms. The Federal Register notice this week is the bureaucratic follow-through that turns that approval into a tradable review voucher.

Under section 529 of the FD&C Act, FDA awards a transferable priority review voucher when a qualifying rare pediatric disease product is approved. The Oct. 6 Federal Register notice is the required public stamp that FAYUVI met the criteria. Ultragenyx can use the voucher to speed another filing or sell it. The notice does not set a market price.

FAYUVI also carried Orphan Drug, Fast Track, and Breakthrough Therapy designations on the way to approval. Manufacturing is under Ultragenyx’s biologics license, with single-dose vials at 1.0 × 10^13 vector genomes per mL.

My take

Two clocks matter. Sept. 17 was the medical clock: a first approved option for a brutal childhood disease. Oct. 6 is the finance clock: a voucher that can bankroll the next rare-disease program. Access, price, and how early kids are treated will decide whether the label’s “preserved neurodevelopmental function” window is wide enough once real clinics start scheduling infusions.